Top
Introduction
Results
Exclusions
Heterogeneity
Discussion
Conclusion
Study Notes
Methods and Data
Supplementary
References

All studies
Mortality
Ventilation
ICU admission
Hospitalization
Progression
COVID-19 cases
Peer reviewed
Symptomatic
Exclusions

Feedback
Home
Show Outline
Top   Intro   Results   Exc.   Heterogeneity   Discussion   Conclusion   StudyNotes   Appendix   SupplementarySupp.   ReferencesRef.
Home   COVID-19 treatment studies for Ibuprofen  COVID-19 treatment studies for Ibuprofen  C19 studies: Ibuprofen  Ibuprofen   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Ibuprofen for COVID-19: real-time meta analysis of 12 studies
Covid Analysis, October 6, 2022, DRAFT
https://c19early.com/ibmeta.html
 
0 0.5 1 1.5+ All studies -1% 12 54,527 Improvement, Studies, Patients Relative Risk Mortality -2% 8 50,525 Ventilation -12% 1 403 ICU admission -40% 1 403 Hospitalization -13% 2 397 Progression -9% 3 4,160 Cases -1% 2 0 Peer-reviewed -3% 10 27,085 Symptomatic -3% 11 54,527 Prophylaxis -1% 10 53,727 Early -51% 2 800 Ibuprofen for COVID-19 c19early.com/ib Oct 2022 Favorsibuprofen Favorscontrol after exclusions
Meta analysis using the most serious outcome reported shows 1% [-8‑10%] higher risk, without reaching statistical significance.
0 0.5 1 1.5+ All studies -1% 12 54,527 Improvement, Studies, Patients Relative Risk Mortality -2% 8 50,525 Ventilation -12% 1 403 ICU admission -40% 1 403 Hospitalization -13% 2 397 Progression -9% 3 4,160 Cases -1% 2 0 Peer-reviewed -3% 10 27,085 Symptomatic -3% 11 54,527 Prophylaxis -1% 10 53,727 Early -51% 2 800 Ibuprofen for COVID-19 c19early.com/ib Oct 2022 Favorsibuprofen Favorscontrol after exclusions
Concerns have been raised over potential harm from the use of ibuprofen for COVID-19 [Day], due to ACE2 upregulation; disrupting normal and beneficial action of the immune system; and delayed diagnosis. There is very limited clinical data currently, especially with regard to acute usage at onset of inefection, and there are no RCTs. Current studies do not show a significant difference in outcomes.
All data to reproduce this paper and sources are in the appendix.
Highlights
We show traditional outcome specific analyses and combined evidence from all studies, incorporating treatment delay, a primary confounding factor in COVID-19 studies.
Real-time updates and corrections, transparent analysis with all results in the same format, consistent protocol for 47 treatments.
A
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rinott -21% 1.21 [0.33-4.38] death 3/87 9/316 Improvement, RR [CI] Treatment Control Abu Esba -170% 2.70 [0.33-22.0] death 40 (n) 357 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.47 Early treatment -51% 1.51 [0.51-4.51] 3/127 9/673 -51% improvement Choi (PSM) -240% 3.40 [0.64-18.1] progression case control Improvement, RR [CI] Treatment Control Samimagham -100% 2.00 [1.33-3.02] death 63 (n) 95 (n) Kragholm 4% 0.96 [0.72-1.23] progression 264 (n) 3,738 (n) Wong -23% 1.23 [0.90-1.68] death Reese (PSM) 9% 0.91 [0.62-1.35] death 5,737 (n) 5,737 (n) Drake 10% 0.90 [0.71-1.13] death n/a n/a Leal 3% 0.97 [0.94-1.00] cases n/a n/a Campbell (PSW) 0% 1.00 [0.99-1.01] death 1,814 (n) 20,311 (n) Xie -12% 1.12 [0.92-1.38] hosp. OT​1 Loucera 48% 0.52 [0.34-0.78] death 519 (n) 15,449 (n) Tau​2 = 0.01, I​2 = 68.3%, p = 0.9 Prophylaxis -1% 1.01 [0.92-1.10] 0/8,397 0/45,330 -1% improvement All studies -1% 1.01 [0.92-1.10] 3/8,524 9/46,003 -1% improvement 12 ibuprofen COVID-19 studies c19early.com/ib Oct 2022 Tau​2 = 0.01, I​2 = 62.5%, p = 0.86 Effect extraction pre-specified(most serious outcome, see appendix) 1 OT: comparison with other treatment Favors ibuprofen Favors control
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rinott -21% death Improvement Relative Risk [CI] Abu Esba -170% death Tau​2 = 0.00, I​2 = 0.0%, p = 0.47 Early treatment -51% -51% improvement Choi (PSM) -240% progression Samimagham -100% death Kragholm 4% progression Wong -23% death Reese (PSM) 9% death Drake 10% death Leal 3% case Campbell (PSW) 0% death Xie -12% hospitalization OT​1 Loucera 48% death Tau​2 = 0.01, I​2 = 68.3%, p = 0.9 Prophylaxis -1% -1% improvement All studies -1% -1% improvement 12 ibuprofen COVID-19 studies c19early.com/ib Oct 2022 Tau​2 = 0.01, I​2 = 62.5%, p = 0.86 Protocol pre-specified/rotate for details1 OT: comparison with other treatment Favors ibuprofen Favors control
Figure 1. A. Random effects meta-analysis. This plot shows pooled effects, discussion can be found in the heterogeneity section, and results for specific outcomes can be found in the individual outcome analyses. Effect extraction is pre-specified, using the most serious outcome reported. For details of effect extraction see the appendix. B. Scatter plot showing the distribution of effects reported in studies. C. History of all reported effects (chronological within treatment stages).
Introduction
We analyze all significant studies concerning the use of ibuprofen for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random effects meta-analysis results for all studies, for studies within each treatment stage, for individual outcomes, for peer-reviewed studies, for Randomized Controlled Trials (RCTs), and after exclusions.
Figure 2 shows stages of possible treatment for COVID-19. Prophylaxis refers to regularly taking medication before becoming sick, in order to prevent or minimize infection. Early Treatment refers to treatment immediately or soon after symptoms appear, while Late Treatment refers to more delayed treatment.
Figure 2. Treatment stages.
Results
Figure 3 shows a visual overview of the results, with details in Table 1 and Table 2. Figure 4, 5, 6, 7, 8, 9, 10, 11, and 12 show forest plots for a random effects meta-analysis of all studies with pooled effects, mortality results, ventilation, ICU admission, hospitalization, progression, cases, peer reviewed studies, and non-symptomatic vs. symptomatic results.
0 0.5 1 1.5+ ALL STUDIES MORTALITY VENTILATION ICU ADMISSION HOSPITALIZATION PROGRESSION CASES PEER-REVIEWED After Exclusions ALL STUDIES All Prophylaxis Early Ibuprofen for COVID-19 C19EARLY.COM/IB OCT 2022
Figure 3. Overview of results.
Treatment timeNumber of studies reporting positive effects Total number of studiesPercentage of studies reporting positive effects Random effects meta-analysis results
Early treatment 0 2 0.0% -51% improvement
RR 1.51 [0.51‑4.51]
p = 0.47
Prophylaxis 5 10 50.0% -1% improvement
RR 1.01 [0.92‑1.10]
p = 0.9
All studies 5 12 41.7% -1% improvement
RR 1.01 [0.92‑1.10]
p = 0.86
Table 1. Results by treatment stage.
Studies Early treatment Prophylaxis PatientsAuthors
All studies 12-51% [-351‑49%]-1% [-10‑8%] 54,527 479
With exclusions 11-21% [-338‑67%]-1% [-10‑8%] 54,130 473
Peer-reviewed 10-51% [-351‑49%]-3% [-11‑5%] 27,085 448
Table 2. Results by treatment stage for all studies and with different exclusions.
Loading..
Figure 4. Random effects meta-analysis for all studies with pooled effects. This plot shows pooled effects, discussion can be found in the heterogeneity section, and results for specific outcomes can be found in the individual outcome analyses. Effect extraction is pre-specified, using the most serious outcome reported. For details of effect extraction see the appendix.
Loading..
Figure 5. Random effects meta-analysis for mortality results.
Loading..
Figure 6. Random effects meta-analysis for ventilation.
Loading..
Figure 7. Random effects meta-analysis for ICU admission.
Loading..
Figure 8. Random effects meta-analysis for hospitalization.
Loading..
Figure 9. Random effects meta-analysis for progression.
Loading..
Figure 10. Random effects meta-analysis for cases.
Loading..
Figure 11. Random effects meta-analysis for peer reviewed studies. [Zeraatkar] analyze 356 COVID-19 trials, finding no significant evidence that peer-reviewed studies are more trustworthy. They also show extremely slow review times during a pandemic. Authors recommend using preprint evidence, with appropriate checks for potential falsified data, which provides higher certainty much earlier. Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details.
Loading..
Figure 12. Random effects meta-analysis for non-symptomatic vs. symptomatic results. Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details.
Exclusions
To avoid bias in the selection of studies, we analyze all non-retracted studies. Here we show the results after excluding studies with major issues likely to alter results, non-standard studies, and studies where very minimal detail is currently available. Our bias evaluation is based on analysis of each study and identifying when there is a significant chance that limitations will substantially change the outcome of the study. We believe this can be more valuable than checklist-based approaches such as Cochrane GRADE, which may underemphasize serious issues not captured in the checklists, overemphasize issues unlikely to alter outcomes in specific cases (for example, lack of blinding for an objective mortality outcome, or certain specifics of randomization with a very large effect size), or be easily influenced by potential bias. However, they can also be very high quality.
The studies excluded are as below. Figure 13 shows a forest plot for random effects meta-analysis of all studies after exclusions.
[Abu Esba], substantial unadjusted confounding by indication likely.
Loading..
Figure 13. Random effects meta-analysis for all studies after exclusions. This plot shows pooled effects, discussion can be found in the heterogeneity section, and results for specific outcomes can be found in the individual outcome analyses. Effect extraction is pre-specified, using the most serious outcome reported. For details of effect extraction see the appendix.
Heterogeneity
Heterogeneity in COVID-19 studies arises from many factors including:
Treatment delay.
The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours [McLean, Treanor]. Figure 14 shows a mixed-effects meta-regression for efficacy as a function of treatment delay in COVID-19 studies from 47 treatments, showing that efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.
Figure 14. Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 47 treatments. Early treatment is critical.
Patient demographics.
Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results (as in [López-Medina]).
Effect measured.
Efficacy may differ significantly depending on the effect measured, for example a treatment may be very effective at reducing mortality, but less effective at minimizing cases or hospitalization. Or a treatment may have no effect on viral clearance while still being effective at reducing mortality.
Variants.
There are many different variants of SARS-CoV-2 and efficacy may depend critically on the distribution of variants encountered by the patients in a study. For example, the Gamma variant shows significantly different characteristics [Faria, Karita, Nonaka, Zavascki]. Different mechanisms of action may be more or less effective depending on variants, for example the viral entry process for the omicron variant has moved towards TMPRSS2-independent fusion, suggesting that TMPRSS2 inhibitors may be less effective [Peacock, Willett].
Regimen.
Effectiveness may depend strongly on the dosage and treatment regimen.
Other treatments.
The use of other treatments may significantly affect outcomes, including anything from supplements, other medications, or other kinds of treatment such as prone positioning.
Medication quality.
The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. [Williams] analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. [Xu] analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer.
Meta analysis.
The distribution of studies will alter the outcome of a meta analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though the treatment may be very effective when used earlier.
In general, by combining heterogeneous studies, as all meta analyses do, we run the risk of obscuring an effect by including studies where the treatment is less effective, not effective, or harmful.
When including studies where a treatment is less effective we expect the estimated effect size to be lower than that for the optimal case. We do not a priori expect that pooling all studies will create a positive result for an effective treatment. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations. While we present pooled results for all studies, we also present individual outcome and treatment time analyses, which are more relevant for specific use cases.
Discussion
Publication bias.
Publishing is often biased towards positive results, however evidence suggests that there may be a negative bias for inexpensive treatments for COVID-19. Both negative and positive results are very important for COVID-19, media in many countries prioritizes negative results for inexpensive treatments (inverting the typical incentive for scientists that value media recognition), and there are many reports of difficulty publishing positive results [Boulware, Meeus, Meneguesso]. For ibuprofen, there is currently not enough data to evaluate publication bias with high confidence.
Funnel plot analysis.
Funnel plots have traditionally been used for analyzing publication bias. This is invalid for COVID-19 acute treatment trials — the underlying assumptions are invalid, which we can demonstrate with a simple example. Consider a set of hypothetical perfect trials with no bias. Figure 15 plot A shows a funnel plot for a simulation of 80 perfect trials, with random group sizes, and each patient's outcome randomly sampled (10% control event probability, and a 30% effect size for treatment). Analysis shows no asymmetry (p > 0.05). In plot B, we add a single typical variation in COVID-19 treatment trials — treatment delay. Consider that efficacy varies from 90% for treatment within 24 hours, reducing to 10% when treatment is delayed 3 days. In plot B, each trial's treatment delay is randomly selected. Analysis now shows highly significant asymmetry, p < 0.0001, with six variants of Egger's test all showing p < 0.05 [Egger, Harbord, Macaskill, Moreno, Peters, Rothstein, Rücker, Stanley]. Note that these tests fail even though treatment delay is uniformly distributed. In reality treatment delay is more complex — each trial has a different distribution of delays across patients, and the distribution across trials may be biased (e.g., late treatment trials may be more common). Similarly, many other variations in trials may produce asymmetry, including dose, administration, duration of treatment, differences in SOC, comorbidities, age, variants, and bias in design, implementation, analysis, and reporting.
Figure 15. Example funnel plot analysis for simulated perfect trials.
Conflicts of interest.
Pharmaceutical drug trials often have conflicts of interest whereby sponsors or trial staff have a financial interest in the outcome being positive. Ibuprofen for COVID-19 lacks this because it is off-patent, has multiple manufacturers, and is very low cost. In contrast, most COVID-19 ibuprofen trials have been run by physicians on the front lines with the primary goal of finding the best methods to save human lives and minimize the collateral damage caused by COVID-19. While pharmaceutical companies are careful to run trials under optimal conditions (for example, restricting patients to those most likely to benefit, only including patients that can be treated soon after onset when necessary, and ensuring accurate dosing), not all ibuprofen trials represent the optimal conditions for efficacy.
Early/late vs. mild/moderate/severe.
Some analyses classify treatment based on early/late administration (as we do here), while others distinguish between mild/moderate/severe cases. We note that viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.
Notes.
1 of the 12 studies compare against other treatments, which may reduce the effect seen.
Conclusion
Meta analysis using the most serious outcome reported shows 1% [-8‑10%] higher risk, without reaching statistical significance.
Concerns have been raised over potential harm from the use of ibuprofen for COVID-19 [Day], due to ACE2 upregulation; disrupting normal and beneficial action of the immune system; and delayed diagnosis. There is very limited clinical data currently, especially with regard to acute usage at onset of inefection, and there are no RCTs. Current studies do not show a significant difference in outcomes.
Study Notes
0 0.5 1 1.5 2+ Mortality -170% Improvement Relative Risk Mortality (b) 37% Oxygen therapy -45% Hospitalization -18% Severe case -85% c19early.com/ib Abu Esba et al. Ibuprofen for COVID-19 EARLY TREATMENT Favors ibuprofen Favors control
[Abu Esba] Prospective study of 503 COVID-19 cases in Saudi Arabia, 40 using ibuprofen during infection, and 357 not using NSAIDs, showing no significant differences in outcomes. Results are subject to confounding by indication.
0 0.5 1 1.5 2+ Mortality, day 60 0% Improvement Relative Risk Mortality, day 30 1% c19early.com/ib Campbell et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors control
[Campbell] Retrospective 28,856 COVID-19 patients in the USA, showing no significant difference in mortality for chronic ibuprofen use vs. sporadic NSAID use. Since ibuprofen is available OTC and authors only tracked prescriptions, many patients classified as sporadic users may have been chronic users.
0 0.5 1 1.5 2+ Progression -240% Improvement Relative Risk c19early.com/ib Choi et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors control
[Choi] Retrospective 293 patients in South Korea, showing higher risk of progression with ibuprofen use, without statistical significance.
0 0.5 1 1.5 2+ Mortality 10% Improvement Relative Risk c19early.com/ib Drake et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors control
[Drake] Prospective study of 78,674 COVID-19 patients, showing no significant difference in mortality with ibuprofen use.
0 0.5 1 1.5 2+ Progression 4% Improvement Relative Risk c19early.com/ib Kragholm et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors control
[Kragholm] Retrospective 4,002 COVID-19 patients in Denmark, 264 with ibuprofen prescriptions, showing no significant difference for COVID-19 severity.
0 0.5 1 1.5 2+ Case 3% Improvement Relative Risk c19early.com/ib Leal et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors control
[Leal] UK Biobank retrospective showing no significant difference in cases with ibuprofen use.
0 0.5 1 1.5 2+ Mortality 48% Improvement Relative Risk c19early.com/ib Loucera et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors control
[Loucera] Retrospective 15,968 COVID-19 hospitalized patients in Spain, showing lower mortality with existing use of several medications including metformin, HCQ, aspirin, vitamin D, vitamin C, and budesonide.
0 0.5 1 1.5 2+ Mortality 9% Improvement Relative Risk Severe case -303% c19early.com/ib Reese et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors control
[Reese] N3C retrospective 250,533 patients showing higher COVID-19 severity with ibuprofen use. Note that results for individual treatments are not included in the journal version or v2 of this preprint.
0 0.5 1 1.5 2+ Mortality -21% Improvement Relative Risk Ventilation -12% ICU admission -40% c19early.com/ib Rinott et al. Ibuprofen for COVID-19 EARLY TREATMENT Favors ibuprofen Favors control
[Rinott] Retrospective 403 COVID-19 cases in Israel, showing no significant difference in outcomes with ibuprofen use. Patients were asked about ibuprofen use starting a week before diagnosis of COVID-19 - treatment time may have been early, late, or prophylactic.
0 0.5 1 1.5 2+ Mortality -100% Improvement Relative Risk Severe case -428% Progression -13% c19early.com/ib Samimagham et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors control
[Samimagham] Retrospective 158 COVID-19 patients in Iran, showing higher risk of mortality with ibuprofen use.
0 0.5 1 1.5 2+ Mortality -23% Improvement Relative Risk Mortality (b) 17% c19early.com/ib Wong et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors control
[Wong] Retrospective 2,463,707 people in the UK, showing no significant difference in COVID-19 mortality with NSAID use. Current NSAID users were defined as those ever prescribed an NSAID in the 4 months prior to study start, and non-users were those with no record of NSAID prescription in the same time period.
0 0.5 1 1.5 2+ Hospitalization -12% Improvement Relative Risk Case -8% c19early.com/ib Xie et al. Ibuprofen for COVID-19 Prophylaxis Favors ibuprofen Favors other NSAIDs
[Xie] PSM retrospective 1,697,522 osteoarthritis or back pain patients in the US, showing no significant differences in COVID-19 cases and hospitalization for ibuprofen vs. other NSAIDs.
We performed ongoing searches of PubMed, medRxiv, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Collabovid, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.com. Search terms were ibuprofen, filtered for papers containing the terms COVID-19 or SARS-CoV-2. Automated searches are performed every few hours with notification of new matches. All studies regarding the use of ibuprofen for COVID-19 that report a comparison with a control group are included in the main analysis. Sensitivity analysis is performed, excluding studies with major issues, epidemiological studies, and studies with minimal available information. This is a living analysis and is updated regularly.
We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome specific analyses. For example, if effects for mortality and cases are both reported, the effect for mortality is used, this may be different to the effect that a study focused on. If symptomatic results are reported at multiple times, we used the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days are used. Mortality alone is preferred over combined outcomes. Outcomes with zero events in both arms were not used (the next most serious outcome is used — no studies were excluded). For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcome is considered more important than PCR testing status. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available (after most or all patients have recovered there is no room for an effective treatment to do better). If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low SpO2 is more important than cough. When results provide an odds ratio, we computed the relative risk when possible, or converted to a relative risk according to [Zhang]. Reported confidence intervals and p-values were used when available, using adjusted values when provided. If multiple types of adjustments are reported including propensity score matching (PSM), the PSM results are used. Adjusted primary outcome results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported p-values and confidence intervals followed [Altman, Altman (B)], and Fisher's exact test was used to calculate p-values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1 [Sweeting]. Results are expressed with RR < 1.0 favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.10.7) with scipy (1.9.1), pythonmeta (1.26), numpy (1.23.3), statsmodels (0.13.2), and plotly (5.10.0).
Forest plots are computed using PythonMeta [Deng] with the DerSimonian and Laird random effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Mixed-effects meta-regression results are computed with R (4.1.2) using the metafor (3.0-2) and rms (6.2-0) packages, and using the most serious sufficiently powered outcome.
We received no funding, this research is done in our spare time. We have no affiliations with any pharmaceutical companies or political parties.
We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients). We note that a shorter time may be preferable. Antivirals are typically only considered effective when used within a shorter timeframe, for example 0-36 or 0-48 hours for oseltamivir, with longer delays not being effective [McLean, Treanor].
A summary of study results is below. Please submit updates and corrections at the bottom of this page.
A summary of study results is below. Please submit updates and corrections at https://c19early.com/ibmeta.html.
Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.
[Abu Esba], 11/2/2020, prospective, Saudi Arabia, peer-reviewed, 6 authors, study period 12 April, 2020 - 1 June, 2020, excluded in exclusion analyses: substantial unadjusted confounding by indication likely. risk of death, 169.5% higher, RR 2.70, p = 0.35, treatment 40, control 357, adjusted per study, multivariable.
risk of death, 36.8% lower, HR 0.63, p = 0.68, treatment 40, control 357, Cox proportional hazards.
risk of oxygen therapy, 44.8% higher, RR 1.45, p = 0.64, treatment 40, control 357, adjusted per study, multivariable.
risk of hospitalization, 18.2% higher, RR 1.18, p = 0.64, treatment 40, control 357, adjusted per study, multivariable.
risk of severe case, 84.8% higher, RR 1.85, p = 0.42, treatment 40, control 357, adjusted per study, multivariable.
[Rinott], 9/30/2020, retrospective, Israel, peer-reviewed, median age 45.0, 5 authors, study period 15 March, 2020 - 15 April, 2020. risk of death, 21.1% higher, RR 1.21, p = 0.73, treatment 3 of 87 (3.4%), control 9 of 316 (2.8%).
risk of mechanical ventilation, 11.8% higher, RR 1.12, p = 0.77, treatment 4 of 87 (4.6%), control 13 of 316 (4.1%).
risk of ICU admission, 39.7% higher, RR 1.40, p = 0.56, treatment 5 of 87 (5.7%), control 13 of 316 (4.1%).
Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.
[Campbell], 5/5/2022, retrospective, USA, peer-reviewed, 4 authors, study period 2 March, 2020 - 14 December, 2020. risk of death, no change, OR 1.00, p = 0.54, treatment 1,814, control 20,311, adjusted per study, propensity score weighting, multivariable, day 60, RR approximated with OR.
risk of death, 1.0% lower, OR 0.99, p = 0.23, treatment 1,814, control 20,311, adjusted per study, propensity score weighting, multivariable, day 30, RR approximated with OR.
[Choi], 6/23/2020, retrospective, South Korea, peer-reviewed, median age 29.0, 8 authors, study period 5 March, 2020 - 18 March, 2020. risk of progression, 240.0% higher, OR 3.40, p = 0.26, treatment 6 of 36 (16.7%) cases, 2 of 36 (5.6%) controls, case control OR, propensity score matching.
[Drake], 7/31/2021, prospective, United Kingdom, peer-reviewed, 362 authors, study period 17 January, 2020 - 10 August, 2020. risk of death, 10.0% lower, OR 0.90, p = 0.36, adjusted per study, multivariable, RR approximated with OR.
[Kragholm], 10/21/2020, retrospective, Denmark, peer-reviewed, 13 authors, study period 1 January, 2020 - 30 April, 2020. risk of progression, 4.0% lower, RR 0.96, p = 0.78, treatment 264, control 3,738.
[Leal], 8/16/2021, retrospective, United Kingdom, peer-reviewed, 5 authors, study period 16 March, 2020 - 1 February, 2021. risk of case, 3.0% lower, OR 0.97, p = 0.29, RR approximated with OR.
[Loucera], 8/16/2022, retrospective, Spain, preprint, 8 authors, study period January 2020 - November 2020. risk of death, 48.3% lower, HR 0.52, p = 0.002, treatment 519, control 15,449, Cox proportional hazards, day 30.
[Reese], 4/20/2021, retrospective, USA, preprint, 23 authors. risk of death, 9.0% lower, HR 0.91, p = 0.65, treatment 5,737, control 5,737, propensity score matching, Cox proportional hazards, Table S56.
risk of severe case, 303.0% higher, OR 4.03, p < 0.001, treatment 5,737, control 5,737, propensity score matching, Table S48, RR approximated with OR.
[Samimagham], 7/13/2020, retrospective, Iran, peer-reviewed, 4 authors. risk of death, 100% higher, OR 2.00, p < 0.001, treatment 63, control 95, adjusted per study, multivariable, RR approximated with OR.
risk of severe case, 427.8% higher, RR 5.28, p < 0.001, treatment 14 of 63 (22.2%), control 4 of 95 (4.2%).
risk of progression, 13.1% higher, RR 1.13, p = 0.04, treatment 60 of 63 (95.2%), control 80 of 95 (84.2%), moderate or severe.
[Wong], 1/21/2021, retrospective, United Kingdom, peer-reviewed, median age 53.0, 32 authors, study period 1 March, 2020 - 14 June, 2020. risk of death, 23.0% higher, HR 1.23, p = 0.19, adjusted per study, general population, multivariable.
risk of death, 17.0% lower, HR 0.83, p = 0.37, adjusted per study, rheumatoid arthritis/osteoarthritis patients, multivariable.
[Xie], 7/13/2022, retrospective, USA, peer-reviewed, 9 authors, study period 1 February, 2020 - 31 October, 2020, this trial compares with another treatment - results may be better when compared to placebo. risk of hospitalization, 12.5% higher, HR 1.12, p = 0.26, Open Claims, PharMetrics Plus, both periods combined.
risk of case, 7.6% higher, HR 1.08, p = 0.25, Open Claims, PharMetrics Plus, both periods combined.
Supplementary Data
References
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit